The White House announced plans to launch TrumpRx, a discount medicine platform that will list weight‑loss and fertility drugs from major players like Novo Nordisk, Eli Lilly, and EMD. The move aims to curb prescription costs amid rising healthcare spending.

Industry insiders warn that the inclusion of high‑margin drugs could dent sales, with Novo Nordisk projecting a potential 10‑15% decline in revenue from its flagship weight‑loss line. Eli Lilly and EMD have issued statements cautioning that the platform may erode profit margins.

The initiative follows a broader push to make prescription drugs more affordable, echoing past efforts like the Affordable Care Act’s drug‑price negotiations. Analysts suggest that the platform could force manufacturers to rethink pricing strategies, potentially sparking a shift toward tiered discount models.

Investors will monitor quarterly earnings for signs of revenue compression, while regulators may scrutinize the platform’s compliance with antitrust rules. If the program gains traction, it could set a precedent for other administrations to adopt similar discount schemes, reshaping the pharmaceutical market.